Skip to main content
. 2018 Apr 10;109(5):1570–1575. doi: 10.1111/cas.13556

Table 2.

(A) Treatment‐emergent grade 3/4 adverse events of patients and (B) laboratory abnormalities in patients treated with cabazitaxel (N = 41)

Preferred term n (%)
Grade 3/4
(A) Non‐hematologic laboratory abnormalities
Fatigue 6 (14.6)
Anorexia 4 (9.8)
Nausea 3 (7.3)
(B) Hematologic laboratory abnormalities
Neutrophil count decreased 21 (53.6)
Anemia 4 (9.8)
Platelet count decreased 3 (7.3)
Febrile neutropenia 3 (7.3)